Cyclooxygenase-2 inhibition does not impair block bone grafts healing in rabbit model
- 236 Downloads
Success of alveolar reconstructions using onlay autogenous block bone grafts depends on their adequate integration to the recipient bed influenced by a number of local molecules. Considering the fundamental role of cyclooxygenase (COX-2) in bone repair, the aim of this study was to analyze the effect of its inhibition in the integration of endochondral (EC) iliac crest, and intramembranous (IM) calvaria bone grafts. Thirty-two rabbits were divided into 4 groups: Calvaria Control (CC) and Iliac Control—treated with oral 0.9 % saline solution, and Calvarial-NSAID (C-NSAID) and Iliac-NSAID (I-NSAID) groups—treated with oral 6 mg/Kg non-steroidal anti-inflammatory drug etoricoxib. After 7, 14, 30 and 60 days the animals were euthanized and the specimens removed for histological, histomorphometric and immunohistochemistry analysis. At day 60, a tight integration of IM blocks could be seen with the presence of remodeling bone, whereas integration of EC grafts was mainly observed at the edges of the grafts. A significant higher percentage of bone matrix in the interface region of the CC grafts in comparison to C-NSAID only at day 14, whereas no differences were detected comparing the EC grafts. No differences were observed in Runx-2 and vascular endothelial growth factor (VEGF) immunolabeling when comparing CC and C-NSAID groups, while a significant weaker Runx-2 and VEGF labeling was detected in I-NSAID group at day 60. Although some influence was detected in osteogenesis, it is concluded that drug induced inhibition of COX-2 does not impair onlay bone grafts’ healing of both embryologic origins in rabbits.
KeywordsCOX-2 Autogenous bone grafts Immunohistochemistry Cbfa1/Runx-2 VEGF
The authors are grateful to Maira Cristina Rondina Couto for histology and immunohistochemistry assistance. This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (Grant Numbers 2008/11485-7, 2009/14989-9).
- Brown KM, Saunders MM, Kirsch T, Donahue HJ, Reid JS (2004) Effect of COX-2 specific inhibition on fracture healing in the rat femur. J Bone Joint Surg Am 86A:116–123Google Scholar
- Kanczler JM, Oreffo RO (2008) Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 2(15):100–114Google Scholar
- Miranda SR, Nary Filho H, Padovan LEM, Nicolielo D, Matsumoto MA (2006) Use of platelet-rich plasma under autogenous onlay bone grafts. Clin Oral Implant Res 17(694):699Google Scholar
- Needelman P, Isakson PC (1997) The discovery and function of COX-2. J Rheumatol 24(Suppl 49):6–8Google Scholar
- Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 23(99):9656–9661CrossRefGoogle Scholar
- Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43:775–777PubMedCrossRefGoogle Scholar
- Vaes BL, Ducy P, Sijbers AM, Hendriks JM, van Someren EP, de Jong NG, van den Heuvel ER, Olijve W, van Zoelen EJ, Dechering KJ (2006) Microarray analysis on Runx2-deficient mouse embryos reveals novel Runx2 functions and target genes during intramembranous and endochondral bone formation. Bone 39:724–738PubMedCrossRefGoogle Scholar